Literature DB >> 2601252

Urinary excretion of glycosaminoglycans in normal and stone forming subjects.

Y M Michelacci1, R Q Glashan, N Schor.   

Abstract

There is evidence suggesting that glycosaminoglycans (GAG) are potent inhibitors of growth and aggregation of calcium oxalate crystals in vitro. This finding raises the possibility that the urinary GAG could play an inhibitory role in the urolithiasis. To investigate this hypothesis, a study on the urinary excretion of GAG in normal and stone forming adults and children was undertaken. Different methods were compared, and the best results were obtained when the GAG were measured by densitometry after agarose gel electrophoresis. Although the GAG concentration was increased in the morning urine compared to the 24-hour urine samples, and in males compared to females, the GAG/creatinine ratio was independent of period of urine collection and of sex. So, it was advantageous to express the amounts of urinary GAG as mg/g of creatinine. Children excreted more GAG than adults, with a higher proportion of chondroitin sulfate. We have shown that the stone forming subjects, both adults and children, excreted lower levels of urinary GAG as compared to normal subjects, independently of the metabolic disorder. The proportions between chondroitin sulfate and heparan sulfate and the structures of these GAG were unaltered in the stone formers. These results indicate that there is a definite difference in terms of levels of GAG between normal and stone forming urines, and suggest a correlation between the urinary GAG concentration and urolithiasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2601252     DOI: 10.1038/ki.1989.296

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Calcium oxalate urolithiasis in children: urinary promoters/inhibitors and role of their ratios.

Authors:  Daniel Turudic; Danica Batinic; Anja Tea Golubic; Mila Lovric; Danko Milosevic
Journal:  Eur J Pediatr       Date:  2016-10-11       Impact factor: 3.183

2.  Extracorporeal shock wave lithotripsy and glycosaminoglycans in urine.

Authors:  P Winter; G Schoeneich; K Ganter; S Winter; A Hesse
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

3.  Urinary glycosaminoglycan excretion in healthy and stone-forming children.

Authors:  F Harangi; Z Györke; B Melegh
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

4.  Urinary glycosaminoglycan excretion in urolithiasis.

Authors:  T Akçay; D Konukoğlu; Y Dínçer
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

5.  The glycosaminoglycan content of renal basement membranes in the congenital nephrotic syndrome of the Finnish type.

Authors:  L P Van den Heuvel; J Van den Born; H Jalanko; C H Schröder; J H Veerkamp; K J Assmann; J H Berden; C Holmberg; J Rapola; L A Monnens
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

6.  Glycosaminoglycans in urine and extracorporeal shock wave lithotripsy.

Authors:  P Winter; K Ganter; U Leppin; G Schoeneich; A Hesse
Journal:  Urol Res       Date:  1995

7.  Kidney stone inhibitors in patients with renal stones and endemic renal tubular acidosis in northeast Thailand.

Authors:  Yasushi Nakagawa; Mauricio Carvalho; Prida Malasit; Sumalee Nimmannit; Suchai Sritippaywan; Somkiat Vasuvattakul; Somchai Chutipongtanate; Vipada Chaowagul; Sanga Nilwarangkur
Journal:  Urol Res       Date:  2004-02-03

8.  Glycosaminoglycans in urine and amniotic fluid in congenital nephrotic syndrome of the Finnish type.

Authors:  P Ljungberg
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

9.  Heparan sulfate gene polymorphism in calcium oxalate nephrolithiasis.

Authors:  Metin Onaran; Akin Yilmaz; Ilker Sen; Mehmet Ali Ergun; Ahmet Camtosun; Bora Küpeli; Sevda Menevse; Ibrahim Bozkirli
Journal:  Urol Res       Date:  2008-12-09

10.  Effect of second messenger systems on oxalate uptake in renal epithelial cells.

Authors:  L Calò; T R Wandzilak; P A Davis; A Borsatti; H E Williams
Journal:  Urol Res       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.